CoChat

Discerning the relationship between microglial activation and Alzheimer’s disease

Kreisl, William C. · 2017 · Brain
Cited by 24

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

This scientific commentary refers to ‘Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer’s disease’, by Parbo et al., (doi:10.1093/brain/awx120). Neuroinflammatory responses have long been considered a pathogenic contributor to Alzheimer’s disease. At physiological concentrations amyloid-β activates microglia, triggering a pro-inflammatory cascade as these resident neuroimmune cells attempt to clear amyloid-β from the brain (Maezawa et al., 2011). The resulting release of cytokines, activation of complement, and phagocytosis cause loss of neurons (Neniskyte et al., 2011). Inflammation can lead to hyper-phosphorylation of tau, resulting in aggregation of the neurofibrillary tangles that comprise the second pathological hallmark of Alzheimer’s disease (Ghosh et al., 2013). In turn, extracellular tau activates microglia, potentially causing a positive feedback loop of inflammation and tau pathology that propagates independent of amyloid burden (Serrano-Pozo et al., 2011). Activated microglia therefore may be important mediators of neurodegeneration in Alzheimer’s disease, and a potential target of novel therapy. However, beneficial effects of microglia such as phagocytosis of cellular debris and trophic support are thought to be critical to neural health. An important step in determining the exact role of microglia in the development of Alzheimer’s disease, and thereby in identifying potential pathways for targeted anti-inflammatory treatments, is to clarify the temporal relationship between microglial activation and Alzheimer’s pathogenesis. In this issue of Brain, Parbo and co-workers provide evidence that microglial activation occurs in mild cognitive impairment (MCI), the clinical prodrome of Alzheimer’s disease, and that the magnitude of microglial activation is related to the amount of amyloid deposition in certain neocortical regions (Parbo et al., 2017). Human PET imaging using radioligands for the 18 kDa translocator protein (TSPO) allows investigation of the relationship between microglia and Alzheimer’s disease. TSPO is upregulated by activated microglia, and, while its native function is poorly understood, TSPO remains the only microglial marker available for in vivo imaging (Schain and Kreisl, 2017). In Alzheimer’s autopsy tissue, the majority of TSPO-expressing parenchymal cells are activated microglia, which surround neuritic plaques and vessels with amyloid angiopathy (Cosenza-Nashat et al., 2009). Several clinical Alzheimer’s PET studies have used TSPO radioligands, with 11C-(R)-PK11195 being the most common. While some studies have obtained negative results, many PET studies have shown increased TSPO binding in Alzheimer’s disease (Schain and Kreisl, 2017). The findings that TSPO binding correlates with clinical severity, volume loss, and fluorodeoxyglucose (FDG) hypometabolism suggest that activated microglia are associated with worsening of disease. Whether increased microglial activation occurs before the onset of dementia in Alzheimer’s disease is less clear, as most PET studies have shown no difference in TSPO binding between patients with MCI and controls (Schain and Kreisl, 2017). To better determine whether neuroinflammatory changes are detectable in the prodromal stage of Alzheimer’s disease, Parbo et al. performed TSPO PET imaging with 11C-(R)-PK11195 in 42 patients with MCI and 10 older controls. 11C-(R)-PK-11195 binding was quantified using a supervised cluster method that obviates the need for arterial sampling and has been previously compared to the gold standard method of quantification (Turkheimer et al., 2007). PET imaging with Pittsburgh compound B was used to determine the presence of amyloidopathy and separate MCI patients with biomarker evidence of underlying Alzheimer’s pathophysiology from those without. TSPO PET binding among the two MCI groups and controls was compared using both predefined regions of interest and using a statistical parametric mapping analysis that tests between-group differences in PET data on a voxel-wise basis without requiring a priori definition of regions of interest. The authors first demonstrated a significant group effect of 11C-(R)-PK11195 binding overall using repeated measures ANOVA [F(2,49) = 7.22, P = 0.0018]. Post hoc comparisons showed that 11C-(R)-PK11195 binding was greater in amyloid-positive MCI patients than in the other two groups, with no difference in binding between amyloid-negative MCI patients and controls. However, binding in predefined regions of interest did not differ between groups. Using the voxel-wise approach, Parbo et al. identified clusters where 11C-(R)-PK11195 binding was greater in amyloid-positive MCI patients than in either amyloid-negative MCI patients or controls. These clusters were located in lateral temporal cortices, and to a lesser extent in frontal and parietal cortices. Clusters of increased binding were also found in medial temporal cortex when

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awx151

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

Metadata

Authors
Kreisl, W. C.
Venue
Brain
Published
2017-06-27
Volume
140
Issue
7
Pages
1825-1828
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W2734097288
Cited by
24
References
6
FWCI
0.22
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.